Perspective - (2023) Volume 11, Issue 2
Received: 03-Feb-2023, Manuscript No. IPACLR-23-13624; Editor assigned: 06-Feb-2023, Pre QC No. IPACLR-23-13624; Reviewed: 20-Feb-2023, QC No. IPACLR-23-13624; Revised: 22-Feb-2023, Manuscript No. IPACLR-23-13624; Published: 27-Feb-2023, DOI: 10.36648/2386- 5180.23.11.457
Antibody Drug Conjugates (ADCs) are a promising class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxic activity of chemotherapeutic agents. ADCs have the potential to improve cancer treatment by selectively targeting cancer cells, reducing toxicity to healthy tissues, and improving therapeutic outcomes. In this article, we will discuss the mechanism of action of ADCs, their development, and their potential applications in cancer therapy.
Targeting cancer cells, Cancer therapy, Cytotoxic activity, Chemotherapeutic agents.
Targeting cancer cells, Cancer therapy, Cytotoxic activity, Chemotherapeutic agents.
Antibody drug conjugates (ADCs) are a class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. The basic premise of ADCs is to use antibodies to deliver a cytotoxic agent specifically to cancer cells, while sparing normal cells. This targeted approach can potentially increase the efficacy of cancer treatment while minimizing toxicity.
The mechanism of action of ADCs involves three key components: The monoclonal antibody, the cytotoxic drug, and the linker that connects the two [1]. The monoclonal antibody component of the ADC binds to a specific antigen that is overexpressed on the surface of cancer cells. Once the antibody binds to the antigen, the ADC is internalized by the cancer cell.
The cytotoxic drug component of the ADC is designed to be released from the antibody in a controlled manner inside the cancer cell. This release is facilitated by the linker, which is designed to be stable in circulation but labile in the intracellular environment of the cancer cell. Once the cytotoxic drug is released, it can exert its toxic effects on the cancer cell. There are several different mechanisms by which ADCs can induce cancer cell death. One of the most common mechanisms is to disrupt the microtubule network, which is necessary for cell division. The cytotoxic drugs used in ADCs, such as auristatins and maytansinoids, bind to tubulin and disrupt microtubule assembly, leading to cell cycle arrest and apoptosis.
Another mechanism by which ADCs can induce cancer cell death is through the induction of DNA damage. Cytotoxic drugs such as calicheamicins and duocarmycins are potent DNA-damaging agents that can induce double-stranded breaks in the cancer cell's DNA, leading to cell death. Finally, ADCs can also induce cell death by triggering an immune response against the cancer cell. Some ADCs, such as Brentuximab vedotin, are designed to bind to antigens that are expressed on the surface of cancer cells and are also recognized by immune cells. This can lead to the activation of immune cells, such as natural killer cells, which can then attack and kill the cancer cells.
The development of ADCs involves several stages, including target identification, antibody selection, linker design, and cytotoxic agent selection. Target identification involves identifying antigens that are expressed specifically on cancer cells [2]. Antibody selection involves selecting a monoclonal antibody that recognizes the target antigen with high specificity and affinity. Linker design involves selecting a linker that can release the cytotoxic agent specifically within cancer cells, minimizing toxicity to healthy tissues. Cytotoxic agent selection involves selecting a cytotoxic agent that can kill cancer cells efficiently and selectively.
ADCs have shown promise in the treatment of various types of cancer, including breast cancer, lung cancer, and lymphoma. Some of the approved ADCs include ado-trastuzumab emtansine (Kadcyla®) for the treatment of HER2-positive breast cancer, brentuximab vedotin (Adcetris®) for the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma, and inotuzumab ozogamicin (Besponsa®) for the treatment of acute lymphoblastic leukemia.
The development of new ADCs is an active area of research, with several new ADCs in various stages of clinical development. In addition, the optimization of linker design and cytotoxic agent selection is ongoing, with the goal of improving the efficacy and safety of ADCs. Moreover, the use of ADCs in combination with other cancer therapies, such as immune checkpoint inhibitors, is being explored, with the hope of improving therapeutic outcomes and overcoming resistance to treatment.
Antibody drug conjugates (ADCs) are a promising class of therapeutic agents that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. ADCs consist of three components: an antibody that targets a specific antigen on the surface of cancer cells, a cytotoxic drug that kills the cancer cells, and a linker that attaches the drug to the antibody [3]. This article will discuss the mechanism of action of ADCs and their potential as a targeted therapy for cancer.
The mechanism of action of ADCs can be divided into three steps: binding, internalization, and drug release. The first step involves the binding of the ADC to the specific antigen on the surface of cancer cells. This binding is mediated by the antibody component of the ADC, which recognizes and binds to the antigen with high specificity and affinity.
Once the ADC has bound to the cancer cell, it is internalized through receptor-mediated endocytosis. This process involves the formation of clathrin-coated pits on the surface of the cancer cell, which then invaginate and pinch off to form intracellular vesicles. The ADC is then transported to the lysosomes, which are cellular organelles responsible for the degradation of cellular components [4].
The final step in the mechanism of action of ADCs is the release of the cytotoxic drug from the antibody in the lysosome. This step is facilitated by the linker component of the ADC, which is designed to be stable in the extracellular environment but labile in the acidic environment of the lysosome. Once the linker is cleaved, the cytotoxic drug is released and can diffuse into the cytoplasm of the cancer cell, where it exerts its cytotoxic effects.
The cytotoxic drugs used in ADCs are typically highly potent chemotherapeutic agents, such as maytansinoids or auristatins, which are too toxic to be administered systemically. By attaching these drugs to antibodies, the cytotoxic effects can be targeted specifically to cancer cells, minimizing toxicity to healthy tissues. ADCs have several advantages over traditional chemotherapy. Firstly, they can selectively target cancer cells while sparing healthy tissues, reducing the risk of systemic toxicity [5]. Secondly, they can deliver high concentrations of cytotoxic drugs directly to cancer cells, increasing their efficacy. Finally, they can overcome resistance to chemotherapy by targeting specific molecular pathways that are overexpressed in cancer cells.
ADCs represent a promising class of targeted cancer therapies that have the potential to improve cancer treatment by selectively targeting cancer cells and reducing toxicity to healthy tissues. The development and optimization of ADCs is an active area of research, with the goal of improving their efficacy and safety. With continued research and development, ADCs have the potential to transform cancer treatment and improve patient outcomes.
Indexed at, Google Scholar, Cross Ref
Indexed at, Google Scholar, Cross Ref
Indexed at, Google Scholar, Cross Ref
Indexed at, Google Scholar, Cross Ref
Citation: Will S (2023) Unlocking the Potential of Antibody Drug Conjugates: A Revolutionary Approach to Targeted Cancer Therapy. Ann Clin Lab Res. Vol.11 No.2:457
